Romidepsin Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 10 mg
Reference Brands: Istodax (USA/EU)
Category:
Oncology Cancer Care
Romidepsin is available in Injection
and strengths such as 10 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Romidepsin is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Romidepsin can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Romidepsin is an anticancer agent used in the treatment of cutaneous T-cell lymphoma (CTCL) and certain types of peripheral T-cell lymphoma (PTCL) in adult patients who have received prior systemic therapy. It is marketed under the brand name Istodax and is administered intravenously under specialist oncology supervision. Romidepsin belongs to a class of compounds known as depsipeptides and is derived from a natural product originally isolated from the bacterium Chromobacterium violaceum.
Pharmacologically, romidepsin functions as a histone deacetylase (HDAC) inhibitor. Following intracellular activation, it binds to HDAC enzymes and blocks their activity, leading to changes in gene expression within malignant cells. These epigenetic modifications result in cell cycle arrest, cellular differentiation, and programmed cell death (apoptosis). In addition to its direct antitumor effects, romidepsin has been shown to inhibit hypoxia-induced angiogenesis and reduce levels of several heat shock protein 90 (Hsp90)-dependent oncoproteins, further contributing to its antineoplastic activity.
Due to its potent mechanism of action and safety considerations, romidepsin therapy requires careful patient selection, monitoring, and administration in controlled clinical settings.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing